

# Hepatitis C: State of Medicaid Access Report Card

## Massachusetts



Grade	Recommendations to Improve Patient Access
<b>A</b>	<ul style="list-style-type: none"> <li>Ensure parity across MassHealth ACOs and MCOs regarding HCV prior authorization requirements.</li> </ul>

### State Overview

As of February 2022, 1,868,990 individuals were enrolled in Medicaid (MassHealth) and CHIP.<sup>1</sup> It is estimated that as of 2016, 38,100 people were living with HCV in Massachusetts.<sup>2</sup> 53.4 percent of MassHealth beneficiaries are enrolled in a Managed Care Organization (MCO)<sup>3</sup>, Accountable Care Organization (ACO)<sup>4</sup> or Accountable Care Partnership Plan (ACCP)<sup>5</sup>. The remaining beneficiaries participate in Primary Care Case Management (PCCM) programs (38.4 percent) operated by the state or Fee-For-Service (FFS) programs (8.2 percent).<sup>6</sup> MassHealth contracts with sixteen ACOs and two MCOs: Be Healthy Partnership, Berkshire Fallon Health Collaborative, BMC HealthNet Plan Community Alliance, BMC HealthNet Plan Mercy Alliance, BMC HealthNet Plan Signature Alliance, BMC HealthNet Plan Southcoast Alliance, Community Care Cooperative, Fallon 365 Care, Mass General Brigham, My Care Family, Steward Health Choice, Tufts Health Together with Atrius Health, Tufts Health Together with BIDCO, Tufts Health Together with Boston Children's ACO, Tufts Health Together with CHA, Wellforce Care Plan, BMC HealthNet Plan, and Tufts Health Together.<sup>7</sup>

The Massachusetts Medicaid Preferred Drug List includes ledipasvir/sofosbuvir, Mavyret, and sofosbuvir/velpatasvir.<sup>8</sup>

Deductions		Policy
Prior Authorization		Prior authorization is not required for preferred HCV treatment regimens for patients who meet the following SmartPA criteria: age ≥ three years old; no paid MassHealth pharmacy claims for hepatitis C drug in all claims history; no paid MassHealth pharmacy claims for drugs suggestive of decompensated cirrhosis in all claims history; and no history of paid MassHealth pharmacy claims in the past 90 days for a drug that may lower DAA efficacy. <sup>9</sup>
Fibrosis Restrictions		Massachusetts Medicaid does not impose fibrosis restrictions. <sup>10</sup>
Substance Use Restrictions		Massachusetts Medicaid does not impose substance use restrictions. <sup>11</sup>
Prescriber Restrictions		Massachusetts Medicaid does not impose prescriber restrictions. <sup>12</sup>
Retreatment Restrictions		Massachusetts Medicaid does not impose retreatment restrictions. <sup>13</sup>
Access in Managed Care	-8	Some ACOs and MCOs have not yet implemented the removal of prior authorization for patients who meet SmartPA criteria, such as Fallon Health Collaborative. <sup>14</sup>
Additional Restrictions		Massachusetts Medicaid does not impose additional restrictions. <sup>15</sup>
<b>Total Deductions</b>	<b>-8</b>	<b>Total Score [100-Deductions]</b>
		<b>92</b>
		<b>Grade</b>
		<b>A</b>

### Contact Your State Officials

**MassHealth Medicaid<sup>16</sup>: Amanda Cassel Kraft, Assistant Secretary for MassHealth, Massachusetts Department of Health and Human Services**

1 Ashburn Place, 11<sup>th</sup> floor Room 109, Boston, MA, 02108; Telephone (617) 573-1770

**Pharmacy & Therapeutics Committee<sup>17</sup>: MassHealth Drug Utilization Review (DUR) Program**

Commonwealth Medicine University of Massachusetts Medical School, P.O. Box 2586, Worcester, MA 01613;  
Telephone: (800) 745-7318

## Key Sources

---

**Preferred Drug List:** [MassHealth Preferred Drug List \(May 09, 2022\)](#)

**Clinical Criteria:** [MassHealth, Prior Authorization Requirements \(May 09, 2022\)](#)

**Prior Authorization Form for Patients Not Meeting SmartPA Criteria:** [MassHealth, Hepatitis Antiviral Agents Prior Authorization Request \(February 2022\)](#)

---

<sup>1</sup> Centers for Medicare & Medicaid Services, Medicaid & CHIP in Massachusetts: <https://www.medicaid.gov/state-overviews/stateprofile.html?state=massachusetts>.

<sup>2</sup> HepVu, Local Data: Massachusetts: <https://hepvu.org/local-data/massachusetts/>.

<sup>3</sup> Commonwealth of Massachusetts, Managed Care Organization Plans: <https://www.mass.gov/service-details/managed-care-organization-mco-plan>

<sup>4</sup> Commonwealth of Massachusetts, Primary ACO Plans: <https://www.mass.gov/service-details/primary-care-aco-plans>

<sup>5</sup> Commonwealth of Massachusetts, Accountable Care Partnership Plans: <https://www.mass.gov/service-details/accountable-care-partnership-plan>.

<sup>6</sup> Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2021): <https://perma.cc/SY4K-FFQ5>.

<sup>7</sup> Commonwealth of Massachusetts, ACOs and MCOs: <https://www.mass.gov/service-details/full-list-of-masshealth-acos-and-mcos>.

<sup>8</sup> Preferred Drug List.

<sup>9</sup> Preferred Drug List.

<sup>10</sup> Clinical Criteria.

<sup>11</sup> Clinical Criteria.

<sup>12</sup> Clinical Criteria.

<sup>13</sup> Clinical Criteria.

<sup>14</sup> Fallon Health, MassHealth Formulary (June 2022):

[https://client.formularynavigator.com/Search.aspx?siteCode=8164346221&targetScreen=3&drugBrandListBaseTC=antivirals%257canti-hepatitis%2Bc%2B\(hcv\)%2Bagents](https://client.formularynavigator.com/Search.aspx?siteCode=8164346221&targetScreen=3&drugBrandListBaseTC=antivirals%257canti-hepatitis%2Bc%2B(hcv)%2Bagents)

<sup>15</sup> Clinical Criteria.

<sup>16</sup> National Association of Medicaid Directors, Medicaid Directors: <https://medicaiddirectors.org/who-we-are/medicaid-directors/>.

<sup>17</sup> Commonwealth of Massachusetts, Drug Utilization Review: <https://www.mass.gov/masshealth-drug-utilization-review-dur>.